

Personalised Medical Devices

ARCS 2023

Bec Bateson

A/g Director

Devices Emerging Technology and Diagnostics

Medical Devices Surveillance Branch

Department of Health and Aged Care, TGA




Australian Government

Department of Health and Aged Care
Therapeutic Goods Administration

The challenge

- Easier access to technology (eg: 3D printers) presents new challenges for patient safety / confidence
 - Use of these technologies is increasing
 - Higher risk custom-made medical devices
 - New manufacturers entering the market
- On 25 February 2021 a new framework for the regulation of personalised medical devices commenced



PMD Framework – key features

- Reduced in scope
- Exempt from ARTG inclusion
- Low numbers of supply
- Intended for rare, bespoke devices where no other device is available

Custom-made
Medical Devices



- Can be validated, verified and reproduced
- Manufactured within a design envelope
- Included in the ARTG
- Intended for consistent methods and materials

Patient-matched
medical devices



- End-to-end system for manufacture of a personalised device
- Used by practitioners and professionals
- Within healthcare facilities
- Included in the ARTG
- Devices made using an MDPS are part of the ARTG inclusion for the MDPS

Medical Device
Production
Systems (MDPS)



Stakeholders in healthcare sectors

More than
50,000
stakeholders



3,000+
Audiologists



24,000 Dental
practitioners



3,000+ Dental
laboratories
and
technicians



4,600
Podiatrists



5,000+
Orthotists and
prosthetists




6,000
Optometrists



23,000
Occupational
therapists



17,000 Medical
radiation
practitioners




2,700
Osteopaths

Feedback from healthcare stakeholders



Healthcare practitioners are not sure whether they are regulated and what their regulatory responsibilities to the TGA are



Existing regulation may present a barrier to supply through clinical practice



Point-of-care manufacturing hubs already exist and operate very differently to the concept of an MDPS




The lines between clinical practice and device manufacture are blurring as technology improves



There is an appetite for regulatory amendments that recognise the role of clinical practice and encourage innovation


Feedback from industry stakeholders



The elements of device design and manufacture are (increasingly) no longer the responsibility of one entity




Manufacturers of MDPSs will not take responsibility for devices made in a system they do not directly operate



Pathways to reimbursement need to be considered when introducing new frameworks or refinements




Traditional pre-market approval processes are not always appropriate for personalised medical devices



There is an appetite for regulatory amendments recognising new methods of manufacture and streamlining approval processes

Point-of-care manufacturing



Establish clear boundaries between regulators



Effectively communicate roles and responsibilities



Appropriate regulation to ensure risks are adequately met



Reduction in unnecessary financial and administrative burdens



Positive patient outcomes through timely access to the most appropriate medical devices

Collaboration and consultation

- Australian Health Practitioner Regulation Agency
- National Alliance of Self Regulating Health Professions
- Australian Commission on Safety and Quality in Health Care
- NDIA/NDIS Commission
- State/territory governments
- Private hospitals
- Healthcare practitioners/clinicians



Point-of-care manufacturing

1.

- Data collection (surveys)

2.

- Analysis of the responses

3.

- A national symposium to discuss

4.

- Public consultation of refinements if required

5.

- Consideration of impacts to the regulatory frameworks

6.

- Implementation, communication and education



Looking ahead

1. IMDRF – Personalized Medical Devices Working Group remains open
2. In Australia:
 - a. Public consultation – exempt devices framework
 - b. National symposium with regulators and state/territory governments
 - c. Potential refinements to the legislation
 - d. Education, communication and guidance



Therapeutic Goods Administration (TGA)

Exhibition booth No.1

Want to chat with me further? Come visit us.





Questions?

www.tga.gov.au



Australian Government

Department of Health and Aged Care
Therapeutic Goods Administration